Use of immortal time within survival analysis.
暂无分享，去创建一个
[1] A. Chang,et al. Characterization of dermatitis after PD‐1/PD‐L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case‐control study , 2018, Journal of the American Academy of Dermatology.
[2] R. Salgia,et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.
[3] K. Byth,et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.
[4] K. Byth,et al. Time-Dependent Measurement of Adverse Events. , 2015, JAMA dermatology.
[5] J. Hanley,et al. Avoiding blunders involving 'immortal time'. , 2014, International journal of epidemiology.